Investment Thesis

.

Competitive Moat

characterized by intangible assets, particularly its proprietary mRNA technology and intellectual property. This technology not only allows for rapid vaccine development but also positions the company favorably in various therapeutic areas, creating high switching costs for partners and customers alike. Over the next 5-10 years, this advantage is expected to strengthen as the company expands its pipeline, though competition from established players like Pfizer and emerging biotech firms poses a notable threat.

Growth Engine

Future revenue growth for Moderna is anticipated to stem from its expanding vaccine portfolio and novel therapeutic candidates, which address a growing number of infectious diseases, cancers, and rare conditions. The total addressable market for mRNA-based therapeutics is projected to reach over $100 billion by the end of the decade, fueled by increasing acceptance of mRNA technology and a favorable regulatory landscape. Currently, Moderna is gaining market share in the oncology space, with several candidates in late-stage trials, which could translate into substantial revenue streams.